Respiratory syncytial virus (RSV) investigational vaccine in infants aged 6 and 7 months likely to be unexposed to RSV

Trial Identifier: 204894
Sponsor: GlaxoSmithKline
Start Date: April 2019
Primary Completion Date: January 2020
Study Completion Date: July 2021
Condition: Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Brazil, Minas Gerais Belo Horizonte, Minas Gerais, Brazil, 30130-100
Brazil, São Paulo Ribeirao Preto, São Paulo, Brazil, 14048-900
Canada, Nova Scotia Halifax, Nova Scotia, Canada, B3K 6R8
Canada, Québec Montreal, Québec, Canada, H3T 1C5
Canada, Québec Québec, Canada, G1V 4G2
Colombia Cali, Colombia, 760042
Finland Jarvenpaa, Finland, 04400
Finland Tampere, Finland, 33100
Finland Turku, Finland, 20520
Italy, Lazio Roma, Lazio, Italy, 00165
Mexico Mexico, Mexico, 04530
Panama Panama, Panama, 07126
Panama, Chiriquí Chiriquí, Panama, 0401
Panama, Panamá Panama, Panamá, Panama, 0801
Poland Debica, Poland, 39-200
Poland Gdansk, Poland, 80-542
Poland Trzebnica, Poland, 55-100
Poland Warszawa, Poland, 02-739
Poland Wroclaw, Poland, 50368
Spain Burgos, Spain, 09006
Spain Madrid, Spain, 28041
Spain Madrid, Spain, 28046
Spain Madrid, Spain, 28040
Spain Majadahonda (Madrid), Spain, 28222
Spain Santiago de Compostela, Spain, 15706
Spain Sevilla, Spain, 41014
Spain Valencia, Spain, 46020
Thailand Bangkok, Thailand, 10330
Turkey Eskisehir, Turkey, 26040
Turkey Izmir, Turkey, 35340
Turkey Kayseri, Turkey, 38030
United Kingdom Manchester, United Kingdom, M13 9WL
United Kingdom Southampton, United Kingdom, S016 6YD
United States, Georgia Atlanta, Georgia, United States, 30322
United States, Idaho Nampa, Idaho, United States, 83686
United States, Kentucky Louisville, Kentucky, United States, 40243
United States, Maryland Baltimore, Maryland, United States, 21201